CONSOLIDACION OSEA PDF

PROCESO DE CONSOLIDACIONDE LAS FRACTURAS Dr. Martín, Agustín Dr. IDACIÓN Definición: Proceso de “cicatrización”. coadyuvante en la consolidación de fracturas es controversial en la literatura médica. Métodos: . encontrar una diferencia del 50% en la consolidación ósea. Se realizó un modelo de regresión lineal considerando las variables relacionadas con el tiempo de consolidación las fracturas consolidaron.

Author: Mozahn Meztigar
Country: Jordan
Language: English (Spanish)
Genre: Video
Published (Last): 20 May 2009
Pages: 128
PDF File Size: 4.20 Mb
ePub File Size: 2.82 Mb
ISBN: 280-2-17452-125-9
Downloads: 87058
Price: Free* [*Free Regsitration Required]
Uploader: Nashicage

Manejo desde una unidad del dolor 1. Update on the treatment of osteoporosis.

Management from a unit of pain I. Callejo Orcasitas y A.

CONSOLIDACIÓN ÓSEA by Ana Rosas on Prezi

Ilona Andoin, delegada comercial de Lilly. En Europa se producen 2,7 millones de fracturas por fragilidad, tanto en hombres como mujeres, con un coste directo de 36 billones de euros. Estas fracturas se asocian con un incremento en la morbilidad y mortalidad.

Osteoporosis OP is defined as a skeletal disorder characterized by decreased bone strength, which predisposes to an increase in fracture risk. In Europe produced 2. These fractures are associated with increased morbidity and mortality. The risk of osfa fracture is determined by the presence of one or more risk factors and decreased bone mineral density BMD consolidcaion by Dual Energy technique absortiometry X-ray DEXA densitometry.

The indication for treatment is made based on the absolute risk of fragility fracture. In patients with a low risk of fracture are sufficient hygienic measures, preventing falls and maintaining an adequate intake of calcium and vitamin D.

In patients with a moderate risk should be individualized drug treatment need and initiate treatment in those at high risk of fracture. The most commonly used drugs are bisphosphonates, inhibitors of bone resorption, also used as hormone teriparatide, osteoanabolic drug and monoclonal antibodies such as denosumab. La posibilidad de desarrollar fracturas por fragilidad o bajo impacto es lo que establece la importancia de esta entidad.

La presencia de fractura de cadera, vertebral y no vertebral incrementa el riesgo de otras fracturas y la mortalidad posterior 2. En Europa se producen 2,7 millones de fracturas por fragilidad, tanto en hombres como mujeres, con un coste directo de 36 billones de euros 3.

Sin embargo, no es infrecuente encontrarnos en las Unidades del Dolor a pacientes que acuden por dolor intenso secundario a complicaciones derivadas de la osteoporosis como un aplastamiento vertebral Fig. Es importante reforzar el consumo de alimentos ricos en dicho mineral y no suplementar a quien no tiene deficiencia. A pesar de todo, el efecto del ejercicio sobre DMO es escaso. En un ensayo realizado en 1. No debemos usarlo en pacientes con hipercalcemia. A diferencia de los bifosfonatos, el denosumab no se acumula en el hueso.

  CANONICATUL DUNEI PDF

Actualmente hay estudios en fase III que exploran el efecto del denosumab frente a placebo para investigar si prolonga la supervivencia libre de tumor. Un estudio de unos En un grupo de 1. La osteonecrosis mandibular ONJ puede ser provocada tanto por los bifosfonatos endovenosos como por el denosumab.

Las incidencias observadas en estudios comparativos son similares entre ambos. Habitualmente ocurre dentro de los primeros 6 meses aunque puede aparecer en cualquier momento del mismo. La calcitonina incrementa la DMO a nivel lumbar y en el antebrazo. Reduce el riesgo de fractura vertebral y no presenta efectos sobre las fracturas no vertebrales Los mismos resultados se encontraron en hombres 59por lo tanto no aporta beneficios respecto a la monoterapia.

Osteoporosis prevention, diagnosis and therapy. Scientific advisory council of osteoporosis Canada. Kanis JA, Johnell O. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Assessment of fracture risk. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis.

Factores de Consolidacion Osea. by Zanti VR on Prezi

J Clin Densitom ; Optimization of BMD measurements to identify high risk groups for treatment a test analysis. J Bone Miner Res ; National Osteoporosis Guidelines Group. Clin Endocrinol ;73 4: British Columbia Medical Association.

Diagnosis, Treatment and Fracture Prevention. Assenting the risk of fragility fracture. Calcium and vitamin D controversies. Rheum Dis North Am ;37 3: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in older people: Exercise for preventing and treating osteoporosis in postmenopausal women. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: Systematic review and meta-analyses.

Effectiveness of hip protectors for preventing hip fractures in elderly people: Institute for Clinical Systems Improvement. Diagnosis and Treatment of Osteoporosis. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev ;9: Risedronato for the prevention and treatment of postmenopausal osteoporosis.

  IEC 60099 5 PDF

Cochrane Database Syst Rev ; 4: Etidronate for treating and preventing postmenopausal osteoporosis. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: Results of a randomized, double-blind, placebo-controlled study.

Curr Med Res Opin ; Poor biphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis. Osteoporos Int ;21 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

New Engl J Med ; 3: Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab ;97 7: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med ; Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-years randomized clinical trial.

Un método de terapia génica y células madre ayuda a reconstruir huesos

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. Safety of osteoanabolic therapy: A decade of experience. J Bone Res ;27 Skeletal changes in rats consolidavion daily subcutaneous injections of recombinant human parathyroid hormone for 2 years and relevance to human safety. Toxicol Pathol ; 3: Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use.

Endocr Rev ;26 5: Early changes in biochemical markers of bone formation correlate with improvements consloidacion bone structures during teriparatide therapy. J Clin Endocrinol Metab ;90 7: HPTH treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteporos Int ;1 3: Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl JMed ; Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network metaanalysis.

J Clin Endocrinol Metab ;97 6: Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: Osteoporos Int ;17 Back pain during different sequential treatment regimens of teriparatide: Curr Med Res Opin ;26 8:

Author: admin